Dual-release formulation, a novel principle in L-dopa treatment of Parkinson's disease.
A single morning dose of dual-release formulation was compared with a slow-release formulation of L-dopa plus benserazide in a randomized, double-blind, cross-over study in 16 fluctuating patients with PD. The mean time to "on" was shorter with the dual-release formulation (43 +/- 31 minutes) than with the slow-release formulation (81 +/- 39 minutes) (p < 0.001), whereas the mean time to relapse to "off" was similar for both formulations. The dual-release formulation had a significantly shorter time to reach peak concentration (t(max)) and greater maximum concentration (C(max)) and area under the plasma concentration time curve (AUC(0--5 h)) than the slow-release formulation, whereas apparent elimination half-life (t(1/2)) was similar for both formulations.
Descombes
S
S
Clinical Investigation Center, INSERM U455, Toulouse, France.
Bonnet
A M
AM
Gasser
U E
UE
Thalamas
C
C
Dingemanse
J
J
Arnulf
I
I
Bareille
M P
MP
Agid
Y
Y
Rascol
O
O
D000368:Aged; D001545:Benserazide / Q000008:administration & dosage*; D003692:Delayed-Action Preparations / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D004338:Drug Combinations; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage*; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D013997:Time Factors
D003692:Delayed-Action Preparations; D004338:Drug Combinations; D007980:Levodopa; D001545:Benserazide